

# Chapter 5

## **Post-transcriptional regulation**

- **Co-transcriptional**
- **Post-transcriptional**

## Co-transcriptional

- 5'-capping
- Exon splicing
- 3'-polyadenylation
- RBP binding



mRNP


## Post-transcriptional


- Exon splicing
- Methylation of N6-Adenine
- Editing



Quality control

NRE (nuclear retention elimination)






# How the mRNP is assembled


nucleus

Nuclear membrane

cytoplasm



Gehring et al., Trends in Biochem Sci., in press 2017



mRNA Capping Enzyme: RNA Guanylyl-transferase and 5'-Phosphatase

CAP Binding Complex (nuclear)

Exon-Junction Complex

Essential proteins for export

Nuclear Pore Complex

NPC

(B)

(C)



# Alternative splicing: a pivotal step between eukaryotic transcription and translation

Textbook

*Alberto R. Kornblihtt, Ignacio E. Schor, Mariano Alló, Gwendal Dujardin, Ezequiel Petrillo and Manuel J. Muñoz*

**Abstract** | Alternative splicing was discovered simultaneously with splicing over three decades ago. Since then, an enormous body of evidence has demonstrated the prevalence of alternative splicing in multicellular eukaryotes, its key roles in determining tissue- and species-specific differentiation patterns, the multiple post- and co-transcriptional regulatory mechanisms that control it, and its causal role in hereditary disease and cancer. The emerging evidence places alternative splicing in a central position in the flow of eukaryotic genetic information, between transcription and translation, in that it can respond not only to various signalling pathways that target the splicing machinery but also to transcription factors and chromatin structure.

- RNA processing
- Splicing mechanisms
- Proteins and small RNA involved in splicing





RNA processing  
Capping – Splicing – polyadenylation - editing

- **RNA processing**
- **Splicing mechanisms**
- **Proteins and small RNA involved in splicing**

Socrative

Room:**3CKURJ4KY**


Quiz: RNA processing

## 5' Capping

Figure 1 | **The major co-transcriptional mRNA processing steps.** Human protein names are given throughout.

**a** | The RNA is shown in green; both GTP and the added guanosine cap (Gp) are shown in blue. The mRNA-capping enzyme in metazoans is bifunctional and has both triphosphatase and guanylyl-transferase activities that remove the  $\gamma$ -phosphate of the nascent transcript and transfer GMP from the GTP donor, respectively. The methyl donor *S*-adenosyl-*l*-methionine (SAM) is converted to *S*-adenosyl-*l*-homocysteine (SAH), which results in the 7-methylguanosine cap (shown in pink).

*Bentley, 2014, Nat Rev Genetics 15:163-75.*




## Exon splicing

Figure 1 | **The major co-transcriptional mRNA processing steps.** Human protein names are given throughout.

**b** | Splicing clips out an intron or intervening sequences as a lariat and ligates the flanking exons together through two transesterification reactions. Conserved intronic **splicing elements** are indicated in red. Spliceosomal U1, U2, U4, U5 and U6 small nuclear ribonucleoprotein particles (snRNPs) and U2 auxiliary factor (U2AF) are shown, but numerous spliceosomal proteins are omitted.

*Bentley, 2014, Nat Rev Genetics 15:163-75.*





# Pre-mRNA splicing occurs in two ATP-Independent transesterification reactions

A) first transesterification

B) second transesterification

## Biochemistry of RNA processing



Is the spliceosome a simple machine ?

Not at all....!!

It has more or less the complexity of a ribosome

Indeed, the spliceosome is quite large complex:


- First, since it is formed by some three-hundred proteins and five U-RNAs
- Second, since it goes through dynamic assembly and disassembly

## Architecture of the Spliceosome

Clarisse van der Feltz, Kelsey Anthony, Axel Brilot, and Daniel A. Pomeranz Krummel\*

Department of Biochemistry, Brandeis University, 415 South Street, Waltham, Massachusetts 02454, United States

**ABSTRACT:** Precursor-mRNA splicing is catalyzed by an extraordinarily large and highly dynamic macromolecular assemblage termed the spliceosome. Detailed biochemical and structural study of the spliceosome presents a formidable challenge, but there has recently been significant progress made on this front highlighted by the crystal structure of a 10-subunit human U1 snRNP. This review provides an overview of our current understanding of the architecture of the spliceosome and the RNA–protein complexes integral to its function, the U snRNPs.




**Table 1. Core Subunits of Human U snRNPs**

U snRNP	subunit gene	common subunit name(s) <sup>a</sup>	molecular mass (kDa) <sup>b</sup>	% U snRNP	recognizable domain/functional site <sup>c</sup>
U1 (248.1 kDa)	RNU1	U1 snRNA	53.5	21.6	
	SNRPB, -B2, -D1, -D2, -D3, -E, -F, -G	seven Sm proteins	94.3	38.0	Sm
	SNRNPA	U1-A	31.3	12.6	RRM
	SNRNP70	U1-70k	51.6	20.8	RRM; SR repeat
	SNRNPC	U1-C	17.4	7.0	Znf
U2 (987.4 kDa)	RNU2	U2 snRNA	61.2	6.2	
	SNRPB, -B2, -D1, -D2, -D3, -E, -F, -G	seven Sm proteins	94.3	9.6	Sm
	SNRPA1	U2A'	28.4	2.9	LRR
	SNRPB2	U2B''	25.4	2.6	RRM
	SF3A1	SF3a120	88.9	9.0	SWAP; UBQ domain
	SF3A2	SF3a66	49.3	5.0	Znf
	SF3A3	SF3a60	58.6	5.9	Znf; SAP
	SF3B1	SF3b155	145.8	14.8	HEAT repeat
	SF3B2	SF3b145	100.2	10.1	SAP
	SF3B3	SF3b130	135.5	13.7	DExH/D
	SF3B4	SF3b49	44.4	4.5	RRM
	SF3B5	SF3b10	10.1	1.0	
	SF3B14	SF3b14a; p14	14.6	1.5	RRM
	PHF5A	SF3b14b; Rds3	12.4	1.3	PHD-like
	DDX46	DDX46; hPrp5p	117.4	11.9	DExH/D; SR repeat
	SMNDC1	SPF30/SMNrp	26.7	2.7	Tudor domain
	U5 (1055.7 kDa)	RNU5	U5 snRNA	37.6	3.6
SNRPB, -B2, -D1, -D2, -D3, -E, -F, -G		seven Sm proteins	94.3	8.9	Sm
TXNL4A		U5-15K	16.9	1.6	TRX
SNRNP40		U5-40K	39.3	3.7	WD40
CD2BP2		U5-52K	37.6	3.6	GYF
DDX23		U5-100K; hPrp28	95.6	9.1	DExH/D; SR repeat
PRPF6		U5-102K; hPrp6	106.9	10.1	HAT/TPR repeats
EFTUD2		U5-116K; hSnu114	109.4	10.4	EF2-like fold; GTPase
SNRNP20		U5-200K; hBrr2	244.5	23.2	DExH/D
PRPF8		U5-220k; hPrp8	273.6	25.9	RNase H-fold; RRM; Jab1/MPN
U4/U6 (589.1 kDa)		RNU4	U4 snRNA	46.9	8.0
	RNU6	U6 snRNA	34.6	5.9	
	SNRPB, -B2, -D1, -D2, -D3, -E, -F, -G	seven Sm proteins	94.3	16.0	Sm
	LSM2, -3, -4, -5, -6, -7, -8	seven LSm proteins	78.9	13.4	Sm
	NHP2L1	15.5K	14.2	2.4	
	PPIH	U4/U6-20K; SnuCyp-20	19.2	3.3	cyclophilin-like
	PRPF31	U4/U6-61K; hPrp31	55.5	9.4	Nop
	PRPF4	U4/U6-60K; hPrp4	58.4	9.9	WD40
	PRPF3	U4/U6-90K; hPrp3	77.5	13.1	PWI
	SART3	p110; SART3; hPrp24	109.6	18.6	HAT repeats; RRM



(B)



From: Van der Feltz et al., 2012

## **Do all introns start with GT and end with AG ?**

Not all of them, there is a small number of introns following an alternative rule: they are called AT-AC introns, or also U12-type introns.


How many ?

Less than 0.5%

Is the same spliceosome taking care of them?

No: it is formed by U11, U12, U4atac, U6atac  
While U5 snRNP is in common


# Splicing types



## 3'-end cleavage and Polyadenylation

Figure 1 | **The major co-transcriptional mRNA processing steps.** Human protein names are given throughout.

**c** | 3' ends of mRNAs are formed by coupled cleavage and polyadenylation. **Cleavage** of mammalian pre-mRNAs occurs **~25 bases downstream** of a consensus sequence (AAUAAA) and is carried out by the multi-subunit complex (shown in purple), which comprises cleavage stimulation factor (CstF), cleavage and polyadenylation specificity factor (CPSF) that bears the endonuclease, and cleavage factors I and II (CFIm and CFII). Poly(A) polymerase (PAP) adds the poly(A) tail. 3' ends of non-polyadenylated histone mRNAs (not shown) are also made co-transcriptionally by a cleavage complex that has many subunits in common with CstF and CPSF. The 5'-to-3' RNA exonuclease 2 (XRN2) degrades RNA downstream of the cleavage site and facilitates transcription termination.




# RNA Editing

Figure 1 | **The major co-transcriptional mRNA processing steps.** Human protein names are given throughout.

**d** | Adenosine-to-inosine (A-to-I) editing is carried out by adenosine deaminases acting on RNA (**ADAR**), which deaminate adenosines into inosines. The folded *GLUR-2* pre-mRNA substrate is shown with the exon in blue and intron in grey.

Inosine behaves as a «**G**» in translation and secondary structures



## RNA Editing

Very difficult to detect ! Special sequencing techs and algorithms needed

Classical example is GluA2 glutamate receptor



A to I editing at specific positions leads to critical amino acid substitutions in the receptor subunits, which induce profound alterations of the channel properties.

RNA-seq studies evidenced many other cases, most to be confirmed experimentally.

## Co-transcriptional RNA processing ?

Capping, polyadenylation and splicing are mainly co-transcriptional processes.

Remind: Research Paper -3 (Djebali et al., 2012 – ENCODE)



This picture is taken from Beyer, A. L. & Osheim, Y. N. Splice site selection, rate of splicing, and alternative splicing on nascent transcripts. *Genes Dev.* **2**, 754–765 (1988).

Figure 2 | **The co-transcriptional nature of pre-mRNA processing. a** | Transcription of a gene and co-transcriptional processing of nascent transcripts are shown. 'Miller spread' electron micrograph (left) and its interpretation (right) are shown for a *Drosophila melanogaster* embryonic gene. The electron micrograph shows the DNA template with several engaged RNA polymerase II (Pol II) molecules and their associated nascent RNA transcripts with bound proteins (seen as dark blobs) that extend on either side of the DNA. Grey and white arrows mark introns that are spliced out co-transcriptionally. The black arrow indicates the direction of transcription along the DNA template.



In all eukaryotes, RNA Polymerase II has a typical C-terminal domain (CTD) that is composed of repetitive peptide sequence. Human: (YSPTSPS) (52 repeats)

- CTD is not present in RNA Pol I and RNA Pol III (RNA produced by these undergo a totally different processing)
- Deletion, shortening or mutation of CTD **impairs processing**
- CTD co-immunoprecipitates a number of proteins needed for capping, splicing, poly-adenylation
- Factors needed for splicing and polyadenylation are found all along the transcribed region.

These observations led to the hypothesis that the RNA POL II CTD acts as a **platform** to carry processing factors and enzymes along nascent RNA

PolII CTD carries a number of processing factors & enzymes

b




Figure 2 | The co-transcriptional nature of pre-mRNA processing

## Alternative splicing

H. sapiens      Estimated number of protein-coding genes: ca 20,000  
Estimated number of transcripts: > 80,000  
Estimated number of proteins: 250,000 – 1 million

S. cerevisiae:      253 genes contain introns  
only **3 genes** shown to have alternative splicing

H. sapiens:      >99% predicted to have exon-intron structure  
>95% predicted to undergo alternative splicing

Genecode statistics: <https://www.genecodegenes.org/>

## **Does AS really increase the coding capacity of genomes ?**


The majority of genes show many transcripts:

Some are protein-coding, other are noncoding RNAs

Sometimes alternative transcripts change UTRs (→ post-transcriptional regulation)

Sometimes the coding region is changed (alternative coding exons)


among the first discovered ...



Calcitonin is a 32-aminoacid peptide hormone that is produced by the parafollicular thyroid cells in Humans. The first function of calcitonin is homeostatic: it lowers calcium concentration in blood.


CGRP is produced in both peripheral and central [neurons](#). It is a potent peptide [vasodilator](#) and can function in the transmission of pain. In the spinal cord, the function and expression of CGRP may differ depending on the location of synthesis.

among the first discovered ...



Mutual exclusion of either exon IIIb or IIIc in the fibroblast growth factor 2 RNA will change the specificity of binding of the encoded proteins showing high affinity for Keratinocyte growth factor when expressing IIIb, or for FGF when expressing IIIc..

**Fig. 2.** Alternative splicing of the neurexin genes. (a) Organization of the human gene encoding neurexin I. The exon-intron structure of the human neurexin I gene is depicted (L. Rowen and B. Graveley, unpublished). The constitutive splicing events are indicated below the gene and alternative splicing events are depicted above the gene. The constitutive exons are white and the alternative exons are shaded. Exon 20 is indicated. Human neurexins II and III have a very similar exon-intron organization (L. Rowen and B. Graveley, unpublished). (b) Model for the function of the alternative splicing of exon 20 in  $\beta$ -neurexin I.  $\beta$ -neurexin I (present in the presynaptic cell) lacking sequences encoded by exon 20 can interact with neuroligin



present in the postsynaptic cell, and thus function to initiate synaptogenesis. In contrast,  $\beta$ -neurexin I containing exon 20 encoded sequences can not interact with neuroligins. This form of  $\beta$ -neurexin I might indirectly function in releasing synapses.

## Neurexins


**Drosophila** Dscam gene provides probably the **extreme** example of alternative splicing.

Perhaps the most complex event that takes place during development is the migration and connection of neurons. Even in a 'simple' organism such as *Drosophila melanogaster*, which contains only ~250 000 neurons, accurately wiring neurons together would appear to be a daunting task.

In flies, the gene encoding the Down syndrome cell adhesion molecule (*Dscam*) appears to fulfill at least part of this role. *Dscam* encodes an axon guidance receptor with an extracellular domain that contains ten immunoglobulin (Ig) repeats. The most striking feature of the *Dscam* gene is that its pre-mRNA can be alternatively spliced into over 38,000 different mRNA isoforms (Fig. 3a). This is 2–3 times the number of predicted genes in the entire organism !

Each mRNA encodes a distinct receptor with the potential ability to interact with different molecular guidance cues, directing the growing axon to its proper location.






Potentially 38,000 splicing variants

## «Pure» alternative splicing


Exon skipping 38%



Alternative 5' splice sites 18%



Alternative 3' splice sites 8%



Intron retention 3%



Mutually exclusive (% Unknown)




Figure 3

Types of alternative splicing.

In all five examples of alternative splicing, **constitutive** exons are shown in **red** and **alternatively spliced** regions in **green**, introns are represented by solid lines, and dashed lines indicate splicing activities. Relative abundance of alternative splicing events that are conserved between human and mouse transcriptomes are shown above each example (in % of total alternative splicing events).

From: Ast G. (2004)

Nature Rev Genetics 5: 773.

**Note that the indicated percentages derive from older studies and are slightly different from those demonstrated by recent, RNA-Seq based evaluations**

Exons that are always present in processed transcripts are said «**constitutive**» or «strong» exons

Exons that are present only in some processed transcripts are called «**alternative**» or «weak» exons

## Alternative exon inclusion/exclusion : regulated process

- Exon-intron border sequence (splice-sites)
- Exon definition (intron definition in lower eukaryotes)
- SR and hnRNPs factors
- *cis*-elements and *trans*-regulatory factors
- Tissue-specific Splicing Regulators
- Nucleosome positioning over exons
- Histone PTMs and readers-splicing factors association
- Transcriptional speed and pausing





Can **alternative exons** be distinguished from **constitutive exons** structurally?

Some Authors used comparative genomics to obtain insight. Human and mouse transcriptomes are quite well characterized, making it possible to classify exons as constitutive or alternative based on real expression data (microarrays, RNA-seq).

Sequences were then compared. Exons were normalized in length and flanking introns were explored within 200 pb.

From Kim et al., 2007, BioEssays 30:38–47

**A****Constitutive - strong****B****Alternative - weak**

## 2.1 Features of **Alternative** versus **Constitutive** Exons

### More conserved

Exons that are alternatively spliced in both human and mouse are **more conserved** than constitutive exons

Conservation is higher toward exon edges and extends farther in introns:  
regulatory sequences ?

### Weak splice sites

Cassette exons<sup>(1)</sup> have **weak splice sites**, compared to the strong ones in constitutive exons

### Shorter

Alternative cassette exons are also **shorter** and are flanked by longer introns than constitutively spliced ones.


### Symmetric

The percentage of **symmetrical** exon is definitely higher in alternative exons (symmetrical means “divisible-by-three” number of base pairs)

<sup>(1)</sup>*Cassette exons: refers to exon skipping*



Second point: how Exons (and Introns) are defined



## **SR proteins = splicing regulators**

### Domains:

The most typical domain is an alternating Arginine-Serine domain, called “RS domain”: it is a protein-protein interaction domain.

### Regulation:

SR are phosphorylated at Ser by several kinases → regulates interaction with each other and with other proteins.

### Other interactants:

SR proteins also interact with the CAP-binding protein and with poly-A binding proteins.

### Binding sites:

Mostly at Exons, sometimes also to ISE (intronic splicing enhancers)

### Activity:

Mostly activatory toward the most proximal exon.  
Exon definition.

Canonical SR proteins

RRM=RNA Recognition Motif

SR-like  
(proteins containing  
an RS domain)

Name*	Domains	Binding sequence	Target genes
<i>Canonical SR proteins</i>			
SRp20 (SFRS3)	RRM and RS	GCUCCUCUUC	SRP20, CALCA and INSR
SC35 (SFRS2)	RRM and RS	UGCUGUU	ACHE and GRIA1–GRIA4
ASF/SF2 (SFRS1)	RRM, RRMH and RS	RGAAGAAC	HIPK3, CAMK2D, HIV RNAs and GRIA1–GRIA4
SRp40 (SFRS5)	RRM, RRMH and RS	AGGAGAAGGGA	HIPK3, PRKCB and FN1
SRp55 (SFRS6)	RRM, RRMH and RS	GGCAGCACCUG	TNNT2 and CD44
SRp75 (SFRS4)	RRM, RRMH and RS	GAAGGA	FN1, E1A and CD45
9G8 (SFRS7)	RRM, zinc finger and RS	(GAC) <sub>n</sub>	TAU, GNRH and SFRS7
SRp30c (SFRS9)	RRM, RRMH and RS	CUGGAUU	BCL2L1, TAU and HNRNPA1
SRp38 (FUSIP1)	RRM and RS	AAAGACAAA	GRIA2 and TRD
<i>Other SR proteins</i>			
SRp54	RRM and RS	ND	TAU
SRp46 (SFRS2B)	RRM and RS	ND	NA
RNPS1	RRM and Ser-rich	ND	TRA2B
SRp35	RRM and RS	ND	NA
SRp86 (SRp508 and SFRS12)	RRM and RS	ND	NA
TRA2α	RRM and two Arg-rich	GAAARGARR	dsx
TRA2β	RRM and two RS	(GAA) <sub>n</sub>	SMN1, CD44 and TAU
RBM5	RRM and RS	ND	CD95
CAPER (RBM39)	RRM and RS	ND	VEGF

## **hnRNP proteins** (heterogeneous nuclear Ribo Nucleic Protein)

- Many different families
- Usually bind intronic sites
- Intron definition
- Several other roles have been ascribed to individual members, e.g. cytoplasmic localization.

**Table 1 | Ribonucleoproteins that are involved in pre-mRNA splicing**



Name	Other names	Domains*	Binding sequences	Target genes
hnRNP A1	NA	RRM, RGG and G	UAGGGA/U	SMN2 and RAS
hnRNP A2	NA	RRM, RGG and G	(UUAGGG) <sub>n</sub>	HIV <i>tat</i> and IKBKAP
hnRNP B1				
hnRNP C1	AUF1	RRM	U rich	<i>APP</i>
hnRNP C2				
hnRNP F	NA	RRM, RGG and GY	GGGA and G rich	<i>PLP</i> , <i>SRC</i> and <i>BCL2L2</i>
hnRNP G	NA	RRM and SRGY	CC(A/C) and AAGU	<i>SMN2</i> and <i>TMP1</i>
hnRNP H	DSEF1	RRM, RGG, GYR and GY	GGGA and G rich	<i>PLP</i> , HIV <i>tat</i> and <i>BCL2L1</i>
hnRNP H'				
hnRNP I	PTB	RRM	UCUU and CUCUCU	<i>PTB</i> , <i>nPTB</i> , <i>SRC</i> , <i>CD95</i> , <i>TNTT2</i> , <i>CALCA</i> and <i>GRIN3B</i>
hnRNP L	NA	RRM	C and A rich	<i>NOS</i> and <i>CD45</i>
hnRNP LL	SRRF	RRM	C and A rich	<i>CD45</i>
hnRNP M	NA	RRM and GY	ND	<i>FGFR2</i>
hnRNP Q	NA	RRM and RGG	ND	<i>SMN2</i>

## Identification of RNA binding proteins motifs


Specificity of RNA binding: both «sequence» and «structure» elements

Problems in predicting regulatory motifs:

- Localization (intron length)
- Sometimes dispersed elements
- Sometimes the structural component prevails upon pure sequence



## Box 2 | CLIP and HITS-CLIP methods



Example:


Individual Splicing Factors  
HITS-CLIP profiles mapped  
to genome and compared  
to RNA-Seq profiles.

## High-throughput sequencing and genome mapping

CLIP-seq reads  
mapping

Reference

RNA-seq reads









## 2.3 Sequence elements that promote or repress splicing at adjacent «ss»

*cis* elements

Approach 1 : random select sequences that drive either exon inclusion or exon skipping in experimental model systems

Approach 2: RNA immunoprecipitation using Abs against Splicing Factors (SR, hnRNP, other) and then NGS (RIP, CLIP, HITS-CLIP)

Note: Studies based on pure search of conserved motifs was not successfull: experimental + bioinformatics approaches needed



AS regulatory sequences characterized by de-novo functional assays

Example:

Cell, Vol. 119, 831–845, December 17, 2004, Copyright ©2004 by Cell Press

# Systematic Identification and Analysis of Exonic Splicing Silencers

Zefeng Wang,<sup>1</sup> Michael E. Rolish,<sup>1,2</sup>  
Gene Yeo,<sup>1,3</sup> Vivian Tung,<sup>1</sup>  
Matthew Mawson,<sup>1</sup> and Christopher B. Burge<sup>1,\*</sup>


<sup>1</sup>Department of Biology

<sup>2</sup>Department of Electrical Engineering  
and Computer Science

<sup>3</sup>Department of Brain and Cognitive Sciences  
Massachusetts Institute of Technology  
Cambridge, Massachusetts 02139

## Summary

Exonic splicing silencers (ESSs) are *cis*-regulatory elements that inhibit the use of adjacent splice sites, often contributing to alternative splicing (AS). To systematically identify ESSs, an *in vivo* splicing reporter system was developed to screen a library of random decanucleotides. The screen yielded 141 ESS decamers, 133 of which were unique. The silencer activity of over a dozen of these sequences was also confirmed in a heterologous exon/intron context and in a second cell type. Of the unique ESS decamers, most could be clustered into groups to yield seven putative ESS motifs, some resembling known motifs bound by hnRNPs H and A1. Potential roles of ESSs in constitutive splicing were explored using an algorithm, ExonScan, which simulates splicing based on known or putative splicing-related motifs. ExonScan and related bioinformatic analyses suggest that these ESS motifs play important roles in suppression of pseudoexons, in splice site definition, and in AS.



Following selection, all positive cell clones are extracted

→ RNA

RT-PCR using primers pairs flanking the interrogated exon → cDNA library

The library is sequenced (clone-and-sequence or NGS) → a collection of sequences



Sequences are bioinformatically examined to find one or more «consensus» motifs

Consensus motifs inserted in test exon and validated.

**A**

consensus

**ESS1**    **TTTGTTCCGT**  
**ESS2**    **GGGTGGTTTA**  
**ESS3**    **GTAGGTAGGT**  
**ESS4**    **TTCGTTCTGC**  
**ESS5**    **GGTAAGTAGG**  
**ESS6**    **GGTTAGTTTA**  
**ESS7**    **TTCGTAGGTA**

**B**

A number of similar studies identified putative **motifs for positive and negative regulation** of splicing, classified on effect and position:

**ESE** = exonic splicing enhancer

**ESS** = exonic splicing silencer

**ISE** = intronic splicing enhancer

**ISS** = intronic splicing silencer

ESE (exonic splicing enhancers) were discovered and described first

*Note that the «code» is superimposed to coding sequences*

ESE mutations were identified in various human diseases

When identified motifs are mapped to reference genes collection, it is observed that regulatory motifs spread a little distance from exons into introns, as predicted by mouse-human conservation analysis seen before.

Maps of potential regulatory sequences are obtained.

Regulatory sequences are found primarily close to the 5'-ss and 3'-ss i.e. around exons




Figure 1 | **Elementary alternative splicing events and regulatory elements.**

**A** | In addition to the splice-site consensus sequences, a number of auxiliary elements can influence alternative splicing. These are categorized by their location and activity as exon splicing enhancers and silencers (ESEs and ESSs) and intron splicing enhancers and silencers (ISEs and ISSs). Enhancers can activate adjacent splice sites or antagonize silencers, whereas silencers can repress splice sites or enhancers. Exon inclusion or skipping is determined by the balance of these competing influences, which in turn might be determined by relative concentrations of the cognate RNA-binding activator and repressor proteins.



Regulatory factors

Tissue-specific splicing factors